Fol­low­ing lethal tox re­port, Boehringer scraps plans for high-speed de­vel­op­ment, kills $730M Han­mi deal

Boehringer-In­gel­heim de­cid­ed to abrupt­ly wash its hands of a $730 mil­lion can­cer drug col­lab­o­ra­tion with Han­mi af­ter a South Ko­re­an min­istry linked the ther­a­py to sev­er­al cas­es of se­vere tox­i­c­i­ty — one of which left a pa­tient dead. Boehringer con­firmed the re­port in a re­ply to End­points News ear­ly Fri­day af­ter­noon, say­ing Ko­re­an of­fi­cials had tracked three cas­es of tox­ic epi­der­mal necrol­y­sis, which can spur he­m­or­rhag­ing and res­pi­ra­to­ry fail­ure.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER